HYDROCHLOROTHIAZIDE; SPIRONOLACTONE - Generic Drug Details
What are the generic drug sources for hydrochlorothiazide; spironolactone and what is the scope of patent protection?
Hydrochlorothiazide; spironolactone
is the generic ingredient in three branded drugs marketed by Pfizer, Ascot, Chartwell Rx, Mutual Pharm, Mylan, Purepac Pharm, Rubicon Research, Sun Pharm Industries, Superpharm, Watson Labs, Ivax Pharms, Lederle, Parke Davis, Upsher Smith, Usl Pharma, and Vangard, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.Seven suppliers are listed for this compound.
Summary for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 15 |
| NDAs: | 18 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 11 |
| DailyMed Link: | HYDROCHLOROTHIAZIDE; SPIRONOLACTONE at DailyMed |
Recent Clinical Trials for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | NA |
| Dutch Kidney Foundation | NA |
| Pfizer | PHASE1 |
Pharmacology for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
| Drug Class | Aldosterone Antagonist Thiazide Diuretic |
| Mechanism of Action | Aldosterone Antagonists |
| Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | hydrochlorothiazide; spironolactone | TABLET;ORAL | 086026-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Purepac Pharm | SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; spironolactone | TABLET;ORAL | 087999-001 | Nov 6, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Usl Pharma | SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | hydrochlorothiazide; spironolactone | TABLET;ORAL | 087651-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ascot | SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; spironolactone | TABLET;ORAL | 088025-001 | Nov 23, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch